AI assistant
NOXOPHARM LIMITED — AGM Information 2017
Nov 28, 2017
65437_rns_2017-11-28_ded5b609-d132-4ead-9797-2ed54b47255f.pdf
AGM Information
Open in viewerOpens in your device viewer
==> picture [180 x 77] intentionally omitted <==
Date: 29 November 2017 Sydney, Australia
ASX: NOX
ASX Limited 20 Bridge Street SYDNEY NSW 2000
Noxopharm Limited
ABN 50 608 966 123
Webcast of Noxopharm Limited 2017 Annual General Meeting
Registered Office:
Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia
Noxopharm Limited ( ASX: NOX), an Australian oncology drug development company, invites shareholders and the market to visit the following link;
http://www.noxopharm.com/irm/content/presentations.aspx?RID=401
Operational Office: Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia
Board of Directors Mr Peter Marks Chairman Non-Executive Director
Dr Graham Kelly Chief Executive Officer Managing Director
Dr Ian Dixon Non-Executive Director
for the webcast recording of the 2017 AGM Presentations.
About Noxopharm
Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of chemotherapy- and radiation-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.
About Nyrada Inc.
Nyrada Inc is a recently formed, New York-based biotechnology company established to house Noxopharm non-oncology drug assets.
Investor & Corporate Enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 9299 9690 E: [email protected] E: [email protected]
Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.